Publish in this journal
Journal Information
Vol. 110. Issue 7.
Pages 518-519 (September 2019)
Vol. 110. Issue 7.
Pages 518-519 (September 2019)
Comentarios Editoriales
DOI: 10.1016/j.adengl.2019.05.014
Full text access
Patient-Reported Outcomes in Psoriasis Validated in Spain: PROs and Cons
Patient reported outcomes en psoriasis validados en España: PROs y contras
Visits
...
L. Puig
Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

This issue of Actas Dermo-Sifiliográficas features a systematic review of studies that have validated or used patient-reported outcome tools in Spanish patients with psoriasis.1 The review includes 5 tools that have been validated for use in Spain: 2 skin disease–specific quality of life questionnaires (the Dermatology Life Quality Index [DLQI] and Skindex-29), 2 psoriasis-specific questionnaires (the Psoriasis Disability Index [PDI]) and PSO-LIFE, which was developed in Spain), and a treatment satisfaction questionnaire (CESTEP), also developed for psoriasis patients in Spain. The authors are to be commended for their review of PRO tools that have been culturally adapted for use in Spain and for evaluating their characteristics.

Among the notable findings of the review is the weak to moderate—and variable—correlation observed between health-related quality of life (HRQoL) measures and clinical severity measured by the Psoriasis Area and Severity (PASI) index. The nature of this correlation can be explained by the fact that PASI may not capture the effects of lesions in certain areas of the body (hands, arms, genitals, scalp, and nails)2 or those of certain symptoms and lesion visibility.3

Although DLQI has a higher floor effect than Skindex-29, which is also more responsive to clinical changes,4 the introduction of a modified DLQI scoring system that takes into account “not relevant” responses5 may help to overcome the notable floor effect of DLQI, which would have particularly important consequences when assessing female, elderly, unemployed, and less well-educated patients.6

Other important considerations are the nonlinear relationship between PASI and HRQoL (greater relative impact for lower PASI scores) and the larger impact of improvements in PASI on HRQoL of women.7 Female sex, together with PASI, is the strongest determinant of PDI in our setting, and it is well-known that disease of equal severity affects women more than men in terms of its impact on DLQI scores and other HRQoL measures in both psoriasis and other chronic inflammatory diseases.8 This greater impact was not determined in this review.

In the discussion section of their article, the authors mention that the three generic HRQoL questionnaires validated for use in Spain—the 36-item Short-Form Health Survey (SF-36), the EuroQol 5D (EQ-5D), and the Nottingham Health Profile (NHP)–have low sensitivity to clinical change. The most useful of these questionnaires is perhaps EQ-5D,9 which has different versions that can be used in psoriasis10,11 and for which algorithms exist to generate utility scores from DLQI scores in patients with psoriasis.12 These scores could be used in pharmacoeconomic studies to define quality-adjusted life years gained with certain therapeutic interventions.

A final point worth noting is the good psychometric properties (internal consistency, reliability, and content and structural validity) observed for CESEPT, the Spanish psoriasis satisfaction treatment questionnaire,13 compared with other psoriasis-specific, skin-specific, and generic measures.14

References
[1]
L. Lizán, C. Gabás-Rivera, I. Belinchón, T. Dilla, T. Huete, S. Díaz.
Instrumentos para la validación de los resultados percibidos por el paciente con psoriasis en España: revisión sistemática de la literatura.
Actas Dermosifiliográficas, (2019),
[2]
M. Augustin, R. Sommer, N. Kirsten, A. Danckworth, M.A. Radtke, K. Reich, et al.
Topology of psoriasis in routine care: Results from high-resolution analysis of 2009 patients.
[3]
B.E. Strober, J.M. van der Walt, A.W. Armstrong, M. Bourcier, A.V.E. Carvalho, E. Chouela, et al.
Clinical goals and barriers to effective psoriasis care.
Dermatol Ther (Heidelb), 9 (2019), pp. 5-18
[4]
P. Fernandez-Peñas, M. Jones-Caballero, O. Espallardo, A. García-Díez.
Comparison of Skindex-29, Dermatology Life Quality Index Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.
Br J Dermatol, 166 (2012), pp. 884-887
[5]
F. Rencz, L. Gulácsi, M. Péntek, A.K. Poór, M. Sárdy, P. Holló, et al.
Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.
Br J Dermatol, 179 (2018), pp. 1102-1108
[6]
F. Rencz, A.K. Poór, M. Péntek, P. Holló, S. Kárpáti, L. Gulácsi, et al.
A detailed analysis of «not relevant» responses on the DLQI in psoriasis: Potential biases in treatment decisions.
J Eur Acad Dermatol Venereol, 32 (2018), pp. 783-790
[7]
K. Geale, M. Henriksson, M. Schmitt-Egenolf.
How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden.
Health Qual Life Outcomes, 15 (2017), pp. 151
[8]
L. Puig, P. Putrik.
Psoriasis: Inequality or individualized care?.
Br J Dermatol, 176 (2017), pp. 1111-1113
[9]
M. Martí-Pastor, A. Pont, M. Ávila, O. Garin, G. Vilagut, C.G. Forero, et al.
Head-to-head comparison between the EQ-5D-5L and the EQ-5D-3L in general population health surveys.
Popul Health Metr, 16 (2018), pp. 14
[10]
F. Hjalte, K.S. Carlsson, M. Schmitt-Egenolf.
Sustained Psoriasis Area and Severity Index Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
Br J Dermatol, 178 (2018), pp. 245-252
[11]
A.K. Poór, F. Rencz, V. Brodszky, L. Gulácsi, Z. Beretzky, B. Hidvégi, et al.
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Qual Life Res, 26 (2017), pp. 3409-3419
[12]
N.J. Davison, A.J. Thompson, A.J. Turner, L. Longworth, K. McElhone, C.E.M. Griffiths, et al.
Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Value Health, 21 (2018), pp. 1010-1018
[13]
M. Ribera, E. Daudén, L. Puig, V.G.P. Briones, J.M. Herranz, X. Bordas, et al.
Diseño y validación de un cuestionario para medir la satisfacción con el tratamiento del paciente con psoriasis moderada y grave: estudio NEODERMA.
Actas Dermosifiliogr, 102 (2011), pp. 28-38
[14]
N. Salame, L.M. Perez-Chada, S. Singh, K. Callis Duffin, A. Garg, A.B. Gottlieb, et al.
Are your patients satisfied a systematic review of treatment satisfaction measures in psoriasis.
Dermatology, 234 (2018), pp. 157-165

Please cite this article as: Puig L. Patient reported outcomes en psoriasis validados en España: PROs y contras. Actas Dermosifiliogr. 2019;110:519–520.

Copyright © 2019. Elsevier España, S.L.U. and AEDV
Idiomas
Actas Dermo-Sifiliográficas (English Edition)

Subscribe to our newsletter

Article options
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
  • Additional material
Tools
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.